Premium
Pseudohalide anions reveal a novel extracellular site for potentiators to increase CFTR function
Author(s) -
Li ManSong,
Cowley Elizabeth A,
Linsdell Paul
Publication year - 2012
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/j.1476-5381.2012.02041.x
Subject(s) - potentiator , cystic fibrosis transmembrane conductance regulator , cystic fibrosis , extracellular , chemistry , secretion , biophysics , ivacaftor , mutagenesis , biochemistry , microbiology and biotechnology , patch clamp , mutant , pharmacology , medicine , biology , gene , receptor
BACKGROUND AND PURPOSE There is great interest in the development of potentiator drugs to increase the activity of the cystic fibrosis transmembrane conductance regulator (CFTR) in cystic fibrosis. We tested the ability of several anions to potentiate CFTR activity by a novel mechanism. EXPERIMENTAL APPROACH Patch clamp recordings were used to investigate the ability of extracellular pseudohalide anions (Co(CN) 6 3− , Co(NO 2 ) 6 3− , Fe(CN) 6 3− , IrCl 6 3− , Fe(CN) 6 4− ) to increase the macroscopic conductance of mutant CFTR in intact cells via interactions with cytoplasmic blocking anions. Mutagenesis of CFTR was used to identify a possible molecular mechanism of action. Transepithelial short‐circuit current recordings from human airway epithelial cells were used to determine effects on net anion secretion. KEY RESULTS Extracellular pseudohalide anions were able to increase CFTR conductance in intact cells, as well as increase anion secretion in airway epithelial cells. This effect appears to reflect the interaction of these substances with a site on the extracellular face of the CFTR protein. CONCLUSIONS AND IMPLICATIONS Our results identify pseudohalide anions as increasing CFTR function by a previously undescribed molecular mechanism that involves an interaction with an extracellular site on the CFTR protein. Future drugs could utilize this mechanism to increase CFTR activity in cystic fibrosis, possibly in conjunction with known intracellularly‐active potentiators.